Shares of Sanofi (NYSE:SNY) have been assigned an average recommendation of “Hold” from the eighteen ratings firms that are presently covering the firm. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $51.50.
A number of analysts have recently commented on the company. TheStreet raised Sanofi from a “hold” rating to a “buy” rating in a research note on Wednesday, July 27th. Zacks Investment Research raised Sanofi from a “sell” rating to a “hold” rating in a research note on Monday, July 25th. Berenberg Bank reissued a “hold” rating and set a $93.00 price target on shares of Sanofi in a research note on Monday, August 15th. BNP Paribas raised Sanofi from an “underperform” rating to a “neutral” rating in a research note on Tuesday, September 13th. Finally, JPMorgan Chase & Co. reissued an “underweight” rating on shares of Sanofi in a research note on Thursday, September 15th.
Sanofi (NYSE:SNY) opened at 38.40 on Friday. The company has a 50 day moving average price of $38.90 and a 200 day moving average price of $40.48. The firm has a market capitalization of $98.84 billion, a price-to-earnings ratio of 21.29 and a beta of 0.98. Sanofi has a 12 month low of $37.41 and a 12 month high of $51.88.
Large investors have recently modified their holdings of the company. Boston Partners increased its stake in shares of Sanofi by 10,203.3% in the second quarter. Boston Partners now owns 7,402,009 shares of the company’s stock worth $309,774,000 after buying an additional 7,330,168 shares during the last quarter. Dodge & Cox increased its stake in shares of Sanofi by 7.2% in the first quarter. Dodge & Cox now owns 53,530,129 shares of the company’s stock worth $2,149,770,000 after buying an additional 3,615,056 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Sanofi by 13.3% in the first quarter. Franklin Resources Inc. now owns 21,232,196 shares of the company’s stock worth $852,684,000 after buying an additional 2,500,421 shares during the last quarter. Hamlin Capital Management LLC acquired a new stake in shares of Sanofi during the second quarter worth $56,725,000. Finally, Hotchkis & Wiley Capital Management LLC increased its stake in shares of Sanofi by 12.5% in the second quarter. Hotchkis & Wiley Capital Management LLC now owns 11,432,112 shares of the company’s stock worth $478,434,000 after buying an additional 1,267,118 shares during the last quarter. Institutional investors and hedge funds own 9.42% of the company’s stock.
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.